抗生素市场-依药物类别（青霉素类、头孢菌素类、大环内酯类、喹诺酮类、氨基糖苷类、四环素类）、类型、谱（宽、窄）、药物来源、给药途径、应用、配销通路、全球预测 2024-2032

由于全球传染病流行率不断上升，预计 2024 年至 2032 年全球抗生素市场CAGR将达到 3.3%。

随着人口成长和都市化进程加快，传染病爆发的风险上升，对有效抗菌治疗的需求增加。根据联合国统计，2022年11月中旬全球人口达80亿，未来30年将增加近20亿。

此外，抗菌素抗药性的持续挑战凸显了对创新抗生素的迫切需求。人们越来越关注医疗基础设施的发展，尤其是在新兴经济体，加上全球医疗支出的不断增加，扩大了对抗生素的需求，推动了市场向前发展。

抗生素市场根据药物类别、类型、光谱、药物来源、给药途径、应用、配销通路和地区进行分类。

预计到 2032 年，青霉素领域的需求将录得强劲，因为青霉素以其对抗从呼吸道感染到皮肤感染等多种细菌感染的功效而闻名。随着医疗程序和手术的进步，术后感染的风险激增，需要使用青霉素等抗生素来预防和治疗。新配方的不断开发和联合疗法的引入增强了对该药物类别的需求。

受成本效益、易于取得以及多种品牌抗生素专利到期等因素的推动，仿製药类型细分市场预计到 2032 年将产生巨额收入。仿製药为品牌抗生素提供了更实惠的替代品，这使得它们在已开发和发展中市场都特别有吸引力。此外，严格的监管审批和品质标准确保了仿製药抗生素的安全性和有效性，进一步推动了其在全球的采用。

受传染病高发生率、完善的医疗基础设施以及旨在对抗抗菌素抗药性的强有力的政府倡议等因素的推动，欧洲抗生素市场规模将在 2032 年大幅扩大。该地区各国优先考虑医疗保健，从而增加了对新型抗生素製剂和疗法的研发活动的投资。此外，製药公司和研究机构之间的策略合作有助于该地区在全球抗生素市场中占据主导地位。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 传染病病率增加
    • 製药和生物技术公司数量不断增加
    • 加强抗生素开发合作
    • 越来越关注仿製药
  • 产业陷阱与挑战
    • 抗生素抗药性
    • 监理复杂性
• 成长潜力分析
• 管道评估
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪錶板

第 5 章：市场估计与预测：按药物类别，2018-2032 年

• 主要趋势
• 青霉素类
• 头孢菌素类
• 大环内酯类
• 奎诺酮类
• 氨基糖苷类
• 四环素类
• 其他药物类别

第 6 章：市场估计与预测：按类型，2018 - 2032

• 主要趋势
• 品牌化
• 泛型

第 7 章：市场估计与预测：按频谱划分，2018 - 2032 年

• 主要趋势
• 广效抗生素
• 窄谱抗生素

第 8 章：市场估计与预测：按药物来源分类，2018 年 - 2032 年

• 主要趋势
• 自然的
• 半合成
• 合成的

第 9 章：市场估计与预测：按管理途径，2018 年 - 2032 年

• 主要趋势
• 口服
• 注射用
• 其他给药途径

第 10 章：市场估计与预测：按应用，2018 - 2032

• 主要趋势
• 呼吸道感染
• 泌尿道感染（UTI）
• 皮肤和软组织感染
• 性传染感染（STI）
• 胃肠道感染
• 其他应用

第 11 章：市场估计与预测：按配销通路划分，2018 年 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 12 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要动向：按地区
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 13 章：公司简介

• Abbott Laboratories
• AbbVie, Inc.
• Allergan plc
• Basilea Pharmaceutica Ltd.
• Bayer AG
• Bristol Myers Squibb
• Cipla Inc.
• Daiichi Sankyo Company Ltd.
• Eli Lilly & Co.
• GlaxoSmithKline plc.
• Johnson & Johnson
• Lupin Inc.
• Melinta Therapeutics LLC
• Merck & Co.
• Novartis AG
• Pfizer Inc.
• Sandoz
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

The global antibiotics market is anticipated to record 3.3% CAGR from 2024 to 2032, owing to the escalating prevalence of infectious diseases worldwide.

As populations expand and urbanization accelerates, the risk of infectious outbreaks rises, necessitating heightened demand for effective antimicrobial treatments. According to the UN, the global population reached 8 billion in mid-November 2022 and will increase by nearly 2 billion people in the upcoming 30 years.

Additionally, the persistent challenge of antimicrobial resistance underscores the urgent need for innovative antibiotics. The increasing focus on healthcare infrastructure development, particularly in emerging economies, coupled with rising medical expenditure globally, amplifies the demand for antibiotics, driving the market forward.

The antibiotics market is classified based on drug class, type, spectrum, drug origin, route of administration, application, distribution channel, and region.

The penicillins segment is predicted to record strong demand by 2032, as they are known for their effectiveness against a wide range of bacterial infections, ranging from respiratory tract infections to skin infections. With the advancements in medical procedures and surgeries, the risk of postoperative infections has surged, necessitating antibiotics like penicillins for prophylactic and therapeutic purposes. The continuous development of novel formulations and the introduction of combination therapies bolster the demand for this drug class.

The generics type segment is expected to generate massive revenues by 2032, fueled by factors such as cost-effectiveness, ease of accessibility, and the expiration of patents for several branded antibiotics. Generic antibiotics offer a more affordable alternative to their branded counterparts, making them particularly attractive in both developed and developing markets. Additionally, stringent regulatory approvals and quality standards ensure the safety and efficacy of generic antibiotics, further driving their adoption globally.

Europe antibiotics market size will expand significantly through 2032 driven by factors such as a high prevalence of infectious diseases, well-established healthcare infrastructure, and strong government initiatives aimed at combating antimicrobial resistance. Countries across the region prioritize healthcare, leading to increased investments in R&D activities focused on novel antibiotic formulations and therapies. Furthermore, strategic collaborations between pharmaceutical companies and research institutions contribute to the region's prominence in the global antibiotics market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Data collection
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of infectious disease
    • 3.2.1.2 Rising number of pharmaceutical and biotechnology companies
    • 3.2.1.3 Growing collaborations for antibiotics development
    • 3.2.1.4 Increasing focus on generic medications
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Antibiotic resistance
    • 3.2.2.2 Regulatory complexities
• 3.3 Growth potential analysis
• 3.4 Pipeline assessment
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2018-2032 ($ Million)

• 5.1 Key trends
• 5.2 Penicillins
• 5.3 Cephalosporins
• 5.4 Macrolides
• 5.5 Quinolones
• 5.6 Aminoglycosides
• 5.7 Tetracyclines
• 5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Branded
• 6.3 Generics

Chapter 7 Market Estimates and Forecast, By Spectrum, 2018 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Broad-spectrum antibiotics
• 7.3 Narrow-spectrum antibiotics

Chapter 8 Market Estimates and Forecast, By Drug Origin, 2018 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Natural
• 8.3 Semisynthetic
• 8.4 Synthetic

Chapter 9 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 Oral
• 9.3 Parenteral
• 9.4 Other routes of administration

Chapter 10 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Million)

• 10.1 Key trends
• 10.2 Respiratory infections
• 10.3 Urinary tract infections (UTIs)
• 10.4 Skin and soft tissue infections
• 10.5 Sexually transmitted infections (STIs)
• 10.6 Gastrointestinal infections
• 10.7 Other applications

Chapter 11 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

• 11.1 Key trends
• 11.2 Hospital pharmacies
• 11.3 Retail pharmacies
• 11.4 Online pharmacies

Chapter 12 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

• 12.1 Key trends, by region
• 12.2 North America
  • 12.2.1 U.S.
  • 12.2.2 Canada
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 France
  • 12.3.4 Spain
  • 12.3.5 Italy
  • 12.3.6 Rest of Europe
• 12.4 Asia Pacific
  • 12.4.1 Japan
  • 12.4.2 China
  • 12.4.3 India
  • 12.4.4 Australia
  • 12.4.5 South Korea
  • 12.4.6 Rest of Asia Pacific
• 12.5 Latin America
  • 12.5.1 Brazil
  • 12.5.2 Mexico
  • 12.5.3 Rest of Latin America
• 12.6 Middle East & Africa
  • 12.6.1 South Africa
  • 12.6.2 Saudi Arabia
  • 12.6.3 Rest of Middle East & Africa

Chapter 13 Company Profiles

• 13.1 Abbott Laboratories
• 13.2 AbbVie, Inc.
• 13.3 Allergan plc
• 13.4 Basilea Pharmaceutica Ltd.
• 13.5 Bayer AG
• 13.6 Bristol Myers Squibb
• 13.7 Cipla Inc.
• 13.8 Daiichi Sankyo Company Ltd.
• 13.9 Eli Lilly & Co.
• 13.10 GlaxoSmithKline plc.
• 13.11 Johnson & Johnson
• 13.12 Lupin Inc.
• 13.13 Melinta Therapeutics LLC
• 13.14 Merck & Co.
• 13.15 Novartis AG
• 13.16 Pfizer Inc.
• 13.17 Sandoz
• 13.18 Sanofi
• 13.19 Teva Pharmaceutical Industries Ltd.
• 13.20 Viatris Inc.